Platinum Investment Management’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Platinum Investment Management’s Portfolio CBMG Stock Details CBMG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-135,921	Closed	-$2.04M	–	155
2020 Q2	$2.04M	Sell	135,921 -415,598	-75%	-$5.94M	0.05%	84
2020 Q1	$8.72M	Sell	551,519 -163,832	-23%	-$2.65M	0.22%	42
2019 Q4	$11.6M	Buy	715,351 +11,478	+2%	+$191K	0.23%	40
2019 Q3	$10.5M	Buy	703,873 +30,988	+5%	+$418K	0.23%	37
2019 Q2	$11.1M	Buy	672,885 +19,170	+3%	+$313K	0.26%	34
2019 Q1	$11.3M	Buy	+653,715	New	+$11.9M	0.27%	38

Other funds holding CBMG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Platinum Investment Management's CBMG Position: Q3 2020 in Review

Platinum Investment Management sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q3 2020, closing a stake of 135,921 shares — an estimated $2.04M sold.

Platinum Investment Management first reported a position in CBMG in Q1 2019 and held it in 6 quarters. The position peaked at $11.6M in Q4 2019. 73 funds tracked by Wall St. Rank hold CBMG as of Q3 2020.

Platinum Investment Management reported no remaining Cellular Biomedicine Group, Inc. position as of Q3 2020 after selling out during the quarter.
Platinum Investment Management sold 135,921 Cellular Biomedicine Group, Inc. shares in Q3 2020, an estimated $2.04M.
Platinum Investment Management first reported a position in Cellular Biomedicine Group, Inc. in Q1 2019 and held it in 6 quarters.
Platinum Investment Management's Cellular Biomedicine Group, Inc. position peaked at $11.6M in Q4 2019.
73 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q3 2020.

Based on Platinum Investment Management's 13F filing for Q3 2020, filed 13 Nov 2020.